CClinicalTrials.gg
Active, not recruitingNCT03304223Updated May 11, 2023

IL2 Imaging in Renal Transplantation

An interventional study of [18F]FB-IL2 PET scan in Kidney Transplant Rejection, sponsored by University Medical Center Groningen. Active, not recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-05-11.

Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

After renal transplantation 5 to 10% of patients experience allograft rejection. Rapid and accurate diagnosis is vital for implementation of additional immunosuppressive therapy. Currently, a renal biopsy is essential for the diagnosis of renal allograft rejection. However, this is an intervention associated with complications like bleeding, patient discomfort and hospital admission. Additionally, limited biopsy sample size may lead to false negative results. So, the introduction of a new non-invasive diagnostic tool for allograft rejection could have major implications for the care of renal transplant recipients. For the purpose of visualizing infiltrating T lymphocytes with positron emission tomography (PET), the tracer 18-Fluor-Interleukin-2 ([18F]FB-IL2) has been developed. The investigators hypothesized that a high correlation exists between [18F]FB-IL2 uptake and the extend of T cell infiltration into renal transplants with signs of rejection

02

Conditions studied

  • Kidney Transplant Rejection
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Female or male aged between 18 and 80 years.
  • Renal Transplant recipients
  • The patient understands the purpose and risks of the study and has given written informed consent to participate in the study.
  • All patients will have a clinical indication for renal biopsy.

Exclusion criteria

Exclusion Criteria:

  • Patients with multiple-organ transplants.
  • Female patients who are pregnant or unwilling to use adequate contraception during the study.
  • Claustrophobia
  • Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
  • A clinical reason for an immediate start of a therapeutic intervention with immunosuppressive medication.
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    [18F]FB-IL2 PET scan

    Renal transplant recipients with a clinical suspicion for renal transplant rejection.

    Diagnostic Test: [18F]FB-IL2 PET scan

Interventions

  • Diagnostic test[18F]FB-IL2 PET scan

    \[18F\]FB-IL2 PET scan procedure

05

What researchers measure

Primary outcomes

  1. The ability of the [18F]FB-IL2 PET to detect renal transplant rejection

    Uptake of \[18F\]FB-IL2 in the renal transplant will be correlated to inflammatory infiltrate and histological BANFF score.

    Time frame: At study day 2, when PET procedure is performed.

Secondary outcomes

  1. Uptake of [18F]FB-IL2 and correlation with renal function

    Uptake of \[18F\]FB-IL2 in the renal transplant will be correlated to renal function as measured by 24-hours urine clearance and the Modification of Diet in Renal Disease equation (MDRD).

    Time frame: At study day 2, when PET procedure is performed.

  2. Uptake of [18F]FB-IL2 and correlation with T-cell subpopulations

    Uptake of \[18F\]FB-IL2 in the renal transplant will be correlated to T-cell subpopulations in urine and blood.

    Time frame: At study day 2, when PET procedure is performed.

06

Study locations

1 site
  • University Medical Center Groningen
    Groningen, Netherlands
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03304223
Lead sponsor
University Medical Center Groningen
Responsible party
J.S.F. Sanders (MD, PhD, University Medical Center Groningen) — Principal investigator
First posted
Oct 6, 2017
Start date
Dec 1, 2017
Primary completion
Dec 1, 2022
Completion
Dec 1, 2023 (estimated)
Last update
May 11, 2023

Study contacts

Jan-Stephan F Sanders, MD, PhD
principal investigator · University Medical Center Groningen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion